Mucormysis is a rare but highly aggressive and a fatal infection that affects immunocompromised patients. Mucormycosis infections have increasingly become very common. The survival of such infections is also very poor. Iron metabolism plays a very important role in regulating mucor infections. Deferoxamine predisposes patients to mucormycosisby supplying the fungus containing iron.From these findings, it is possible to treat the infection by using iron chelator as long as the chelator does not supply the fungus containing iron inappropriately. Previous information reveals that the concept of high-dose liposomal amphotericin is the most used monotherapy for mucormycosis (Suresh, 2003). There are, however, several other therapeutic strategies are available. The options include the combination therapy using lipid amphotericin with an azole or an echinocandin (posaconazole or itraconazole) or with all the three. The main principles of therapy for mucor infection remain rapid diagnosis, urgent surgical debridement, early diagnosis, systemic antifungal treatment and reversal of underlying predisposition. Mucormycosisis known to be the second most frequent mold infection in immunocompromised patients and progresses rapidly in both immunocompetent and immunocompromised individuals. The diagnosis of mucor infection in both laboratories and clinics remains difficult which has led to high mortality rates and unsatisfactory treatment.
Interested in a PLAGIARISM-FREE paper based on these particular instructions?...with 100% confidentiality?